Variable | Tocotrienols (n = 43) | Placebo (n = 44) | Pvalue |
---|---|---|---|
Gender (female) | 23 (53.5%) | 30 (68.2%) | 0.160 |
Age in years (range) | 52 ± 9 (36-74) | 49 ± 7 (38-68) | 0.177 |
BMI (kg/m2) | 27.2 ± 4.6 | 27.1 ± 4.6 | 0.873 |
   Normoweight (BMI < 25) | 16 (37.2%) | 14 (31.8%) |  |
  Overweight (25 < BMI < 30) | 16 (37.2%) | 21 (47.7%) |  |
    Obese (30 < BMI < 40) | 11 (25.6%) | 8 (18.2%) |  |
 Morbidly Obese (40 < BMI < 50) | 0 (0.0%) | 1 (2.3%) |  |
TC (mmol/L) | 5.9 ± 0.6 | 5.6 ± 0.6 | 0.075 |
HDL (mmol/L) | 1.44 ± 0.35 | 1.37 ± 0.30 | 0.611 |
LDL (mmol/L) | 3.7 ± 0.6 | 3.6 ± 0.6 | 0.168 |
TG (mmol/L) | 1.5 ± 0.7 | 1.6 ± 0.8 | 0.889 |
ALP (IU/L) | 76 ± 21 | 72 ± 18 | 0.826 |
AST (IU/L) | 36 ± 14 | 38 ± 13 | 0.381 |
ALT (IU/L) | 35 ± 16 | 39 ± 22 | 0.611 |
GGT (IU/L) | 33 ± 19 | 32 ± 19 | 0.712 |
hs-Crp (mg/L) | 4.3 ± 7.1 | 4.0 ± 5.4 | 0.865 |
Apo B (g/L) | 1.25 ± 0.20 | 1.25 ± 0.21 | 0.952 |
Lp(A) (mg/dL) | 17 ± 14 | 16 ± 16 | 0.449 |
Serum creatinine (μmol/L) | 86 ± 13 | 78 ± 11 | 0.008 |
Fasting glucose (mmol/L) | 5.4 ± 0.8 | 6.1 ± 2.3 | 0.557 |
      IFG ≥ 7.0 mmol/L | 2 (4.7%) | 7 (15.9%) |  |
Systolic (mmHg) | 134 ± 18 | 131 ± 15 | 0.524 |
Diastolic (mmHg) | 80 ± 9 | 80 ± 9 | 0.976 |
Tobacco, current users | 5 (11.6%) | 5 (11.4%) | Â |
Mild NAFLD (score 3) | 34 (79.1%) | 35 (79.5%) | Â |
Moderate NAFLD (score 4) | 7 (16.3%) | 8 (18.2%) | Â |
Severe NAFLD (score 5-6) | 2 (4.7%) | 1 (2.3%) | Â |